PET / CT with Ga-68-HA-DOTATATE for Neuroendocrine Tumours

With Ga-68-HA-DOTATATE PET/CT, images can show the presence on cell surface structures (so-called somatostatin receptors) of specific tumours of the gastrointestinal tract (neuroendocrine tumours, so-called NET). Thus, the primary tumour and possible metastases can be detected and evaluation is also possible for treatment with octreotide (so-called sandostatin), or radiolabelled octreotide (Y-90 or Lu-177-DOTATATE, so-called peptide receptor radionuclide therapy, as part of the "theranostic" concept). Here on the one hand, PET (positron emission tomography) is used to image tumour metabolism, on the other hand, the CT (computed tomography, here as "low-dose CT") is used for spatial localisation. The combination of both methods in one examination allows the exact localisation of malignant tumours in a way that it is not possible with other methods. The fees for PET-CT in Germany are not currently covered by the statutory health insurance (GKV) for this indication. We will gladly assist you in creating a cost-transfer application.

The examination may also be indicated for other problems, including the following:

  • Diagnostic localisation for NET tumours (including carcinoid, gastrinoma, insulinoma)
  • Problems involving  recurrent tumour growth after treatment (so-called relapse), metastases.
  • Selection and treatment control with respect to peptide receptor radionuclide treatment 
  • C-cell carcinoma of the thyroid, Merkel Cell Tumour

On the day of the examination, it is not necessary to abstain from food and drinks. Medications containing the active ingredient "octreotide" (Bendatreotid, Sandostatin, Octreotid) must be discontinued 24 hours before the examination. Please bring along to this examination any relevant previous findings. Allow a good 2-3 hours for the examination. 

Diagnostic procedure